Company
Bambusa Therapeutics
Transforming I&I Treatment with Next-Generation Bispecific Antibodies
Also known as Bambusa Therapeutics, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Boston, MA, United States
- Legal name
- Bambusa Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are dedicated to developing innovative bispecific antibodies for immunological and inflammatory (I&I) disorders that transform patient outcomes and enhance quality of life.
Funding snapshot
- Total raised
- $67.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $53.3M2025-02-12
Funding rounds
- Round, 2025
- $53.3M2025-02-12, SEC form D sold, 16 investors
- Round, 2024
- $9M2024-06-12, SEC form D sold, 9 investors
- Round, 2024
- $5.1M2024-06-12, SEC form D sold, 4 investors
Loading relationship preview